Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

3d illustration of human body lung anatomy © Shutterstock / Sebastian Kaulitzki

The investment will enable Optellum to scale its base, operations, and commercial launches in the UK and USA; accelerate research and development; and expand its platform into personalised therapy decisions by integrating imaging data with molecular data, robotics, and liquid biopsies.

Optellum was co-founded by the University of Oxford’s Professor Sir Mike Brady with the mission of seeing every lung disease patient diagnosed and treated at the earliest possible stage, and cured. Founded in 2016, the company provides artificial intelligence decision-support software that assists physicians in early diagnosis and optimal treatment for their patients.

Lung cancer is the most common type of cancer and the leading cause of cancer deaths in the world. Approximately 1.8 million people worldwide die from lung cancer each year. The current five-year survival rate is only 20%, primarily due to most patients being diagnosed after the disease has progressed to an advanced stage (Stage III or IV). However, the survival rate for small tumours treated at Stage IA is as high as 90%. This disparity highlights a critical need for diagnosis and treatment at the earliest stage possible.

Read the full story on the University of Oxford website